By Joseph Burns, from the Volume XXIV, No. 15 – October 30, 2017 issue
MIXED IN THE BAD NEWS concerning the proposed Clinical Laboratory Fee Schedule for 2018, there is some good news regarding what the federal Centers for Medicare and Medicaid Services proposes to pay for certain advanced diagnostic tests.
After analyzing the proposed fee schedule, Quorum Consulting of San Francisco, reported, as other analysts have concluded, that CMS
By Robert Michel, from the Volume XI No. 3 - February 23, 2004 issue
There’s a new player offering clinical diagnostic services in oncology. Genomic Health, Inc., based in Redwood City, California, is now accepting specimens. Last month, its laboratory received all the regulatory clearances required to conduct business. The company’s proprietary technology is incorporated in a test it calls Oncotype DX™ . This clinically-validated diagnostic assay provides a
